Calibr researchers propose versatile CAR T strategy

The Scripps Research Institute designed the new T cell constructs to bind a peptide not present in the human body. When co-administered with an antibody switch -- a tumor antigen-binding antibody fragment conjugated to the peptide -- the T cells are directed by the peptide-antibody conjugate to the tumor to elicit their anti-tumor effects. The idea behind the new design is that the T cell therapy is active and directed to the tumor cells only when the antibody switch is present. ...